# Study of the Bioequivalence and Food Effects of HRX0701 Tablets in Healthy Subjects

> **NCT05415644** · PHASE1 · COMPLETED · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 78 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** hrx0701 tablets、Metformin hydrochloride tablets、Retagliptin phosphate tablets
- **DRUG:** hrx0701 tablets

## Key facts

- **NCT ID:** NCT05415644
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-05
- **Primary completion:** 2022-08-08
- **Final completion:** 2022-08-08
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2022-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05415644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05415644, "Study of the Bioequivalence and Food Effects of HRX0701 Tablets in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05415644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*